Digital Health & HealthAI: the 2026-2027 EMEA circuit

Digital health is not one market. It is the overlap of several: the hospital IT estate and its interoperability problem, the regulated world of medical devices and software-as-a-medical-device, the pharma and biotech data teams now reaching for genomics and machine learning, and the founder-and-investor layer trying to sell into all of them. The events that matter are the ones where these groups are forced into the same building, because a clinical AI tool is worth nothing until a hospital procurement officer, a regulator and a clinician all agree it is safe to deploy.

This index maps the EMEA circuit of those events across 2026 and 2027. They split into recognisable types. There are the large horizontal gatherings where the whole sector convenes: HIMSS Europe for health IT, HLTH Europe for the business of health, MEDICA in Düsseldorf for the device and technology trade. There are the AI-specific conferences, smaller and more technical, where precision medicine, medical imaging and clinical decision support are argued out: the HealthAI conference in Prague, Medica AI hosted at Champalimaud in Lisbon. And there is the national and innovation layer, from the HETT Show serving the NHS to GIANT Health and Frontiers Health, where startups, health systems and capital meet.

What unites them is a single question that has moved to the centre of every programme: how does artificial intelligence get from a research paper into a clinic without breaking trust, regulation or the budget. The events that answer it credibly are the ones worth a delegate's time.

Who is in the room

The audience shifts by event type, but the recurring roles are consistent. Hospital and health-system IT leaders, chief medical information officers and digital transformation directors set the demand side. Medical device and health-tech vendors, from multinational manufacturers to seed-stage startups, set the supply side. Around them sit the people who decide whether a product moves: regulatory and market-access specialists, health economists, clinical researchers, and the investors and corporate development teams who fund the next round. At the AI-specific conferences the mix tilts towards computational biologists, imaging and radiology specialists, data scientists and the clinicians who will be asked to use the output.

How the room actually works

The horizontal trade events run on exhibition floors and procurement intent: visitors come to evaluate working systems, not to listen to keynotes. MEDICA and HIMSS Europe are read this way, as places to assess vendors hands-on. The business and innovation events run on curated networking and capital flow: HLTH Europe, Frontiers Health and GIANT Health are structured around meetings between founders, health systems and investors. The academic and AI conferences run on peer review and demonstration: abstract submission, plenary sessions and live model demonstrations. Knowing which mode an event operates in is the difference between a useful trip and a wasted one.

The seasonal structure

The EMEA digital health calendar has two dense windows. Spring and early summer carry the flagships: HIMSS Europe (May), SANTEXPO in Paris (May) and HLTH Europe in Amsterdam (June). Autumn carries the second wave and most of the AI-specific and innovation events: BioTechX in Basel and the World Health Summit in Berlin in early October, Frontiers Health and the HETT Show in late September and October, the Digital Health congress in Barcelona and MEDICA in Düsseldorf in November, and GIANT Health in London to close the year. The two HealthAI conferences sit in the July gap, between the two main seasons.

The 2026 context

Three forces shape the 2026 programmes. The EU AI Act is now in force and its high-risk classification of much clinical AI is the practical backdrop to every deployment conversation. The European Health Data Space is moving from regulation to implementation, making interoperability and secondary use of health data a live commercial question rather than a policy abstraction. And the funding environment for health-tech has tightened, which has pushed the investor-facing events towards evidence of revenue and clinical adoption over pure innovation narrative. The events that engage these forces directly are the ones setting the agenda.

Trends 2027

Looking 12 to 18 months ahead, the observable signals point in a few directions. Clinical AI is consolidating from pilots into procurement, which favours the trade and procurement-oriented events. Generative AI in clinical documentation and patient communication is the fastest-moving subtheme and is acquiring dedicated tracks. And the line between the health IT events and the pharma and biotech data events is blurring as both converge on the same machine-learning and real-world-evidence questions, a convergence visible in the growth of events like BioTechX that sit deliberately across data, AI and genomics.

Methodology and data standards

This index covers professional and B2B digital health, health IT, MedTech and clinical AI events with a meaningful EMEA footprint. It excludes purely clinical and specialty medical congresses, pharma manufacturing and pharmacy retail fairs, and consumer wellness events, except where they carry a substantial digital health or AI programme. Each record is verified against the official event source for dates, venue and organiser, and is refreshed on a trigger-based cycle as new editions are announced. Where a 2026 edition has already taken place, the record carries the next confirmed edition. Figures attributed to organisers are labelled as such. Scope limitation: coverage is strongest for the large recurring events and the dedicated HealthAI conferences, and is being extended across the national innovation layer.